CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy
Authors
A Goldhirsch
B Fisher
+53 more
B Thürlimann
Basileios Venizelos
C Markopoulos
C Markopoulos
C Markopoulos
C Markopoulos
Christos Markopoulos
D Giudici
D Grady
D Jacobs
Dimitrios Koukouras
E Daly
E Di Salle
E Mamounas
E McCloskey
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
EP Winer
Evagelos Tzoracoleftherakis
F Levi
Food and Drug Administration
G Atalay
G Francini
Grigorios Xepapadakis
Helen Gogas
JC LaRosa
JF Robertson
JN Ingle
John Misitzis
John Papadiamantis
KM Bass
KM Wasan
LJ Gibson
M Elisaf
MH Gail
N Zilembo
NM Laird
PE Goss
PE Goss
PE Lønning
R Jakesz
RC Coombes
RC Coombes
RR Love
S Chia
SB Kritchevsky
T Engan
T Korhonen
Tamoxifen Alone or in Combination) Trialists' Group The ATAC (Arimidex
TR Evans
Urania Dafni
Vasilios Zobolas
WB Kannel
Zoh Antonopoulou
Publication date
16 June 2009
Publisher
BioMed Central
Doi
Cite
View
on
PubMed
Abstract
Abstract is not available.
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 01/04/2019
Springer - Publisher Connector
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 03/05/2017